Clinical trial
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
NCT00030654 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00030654 |
|---|---|
| Title | Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer |
| Official title | A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eastern Cooperative Oncology Group Cancer and Leukemia Group B SWOG Cancer Research Network NRG Oncology |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate |
| Enrollment | 21 |
| Start date | Oct 1, 2002 |
| Primary completion | Feb 4, 2005 |
| Completion | Feb 4, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 22, 2020 |
| Countries | Australia, Peru, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: